Chemotherapy-Induced Anemia Market Size was valued at USD 2.4 Bn in 2023 and is predicted to reach USD 3.9 Bn by 2031 at a 6.5% CAGR during the forecast period for 2024-2031.
Chemotherapy induces anemia, a disorder characterized by decreased hemoglobin and red blood cells. This disease originates from the fast cell division that chemotherapy treatments frequently target. The market is being propelled primarily by the increasing recognition of the significance of anemia management in cancer therapy among both healthcare providers and patients. In addition, the availability of erythropoiesis-stimulating medicines and iron supplements has increased the need for therapies for chemotherapy-induced anemia, which in turn has boosted the growth of the chemotherapy-induced anemia market. Furthermore, market expansions are being propelled by the development of novel therapies, which in turn are being supported by rising investments in cancer research initiatives from governments, private organizations, and pharmaceutical companies, as well as by continuously improving research technologies. In addition, cancer patients’ quality of life has prompted oncologists to place a greater emphasis on effective chemotherapy-induced anemia.
However, the market's expansion is hindered by the stringent regulatory standards of chemotherapy-induced anemia, and creating therapy, researching, and developing strategies to target chemotherapy-induced anemia is a time-consuming and expensive endeavor. In addition, the market expansion is also hindered by the negative effects linked to chemotherapy-induced anemia therapies. Furthermore, factors driving market expansion include an uptick in cancer cases and fatalities globally and a surge in research and development efforts related to the creation of these medications. Chemotherapy-induced anemia is in high demand because cancer rates are increasing globally.
The chemotherapy-induced anemia market is segmented based on a type of anemia, treatment type, drug type, and end-user. Based on anemia, the market is segmented into mild anemia, moderate anemia, severe anemia, and life-threatening anemia. By treatment type, the market is segmented into RBC transfusion, erythropoiesis-stimulating agents (ESAs), and iron supplementation. By drug type, the market is segmented into epogen injection, procrit injection, androxy oral, Aranesp injection, epoetin alfa injection, and others. By end-user, the market is segmented into hospitals, specialty clinics, ambulatory surgical centers, and others.
The mild anemia market in chemotherapy-induced anemia is expected to hold a major global market share in 2023. This is because treating mild anemia, a common side effect among chemotherapy patients, is essential for curative cancer treatment and quality of life maintenance. Because of its ubiquity and the fact that it is in its early stages, mild anemia is more frequently diagnosed and treated than moderate cases.
Hospitals are growing rapidly in the chemotherapy-induced anemia market because they treat a large number of cancer patients through chemotherapy, and many of these patients experience anemia as a side effect. Hospitals offer access to cutting-edge diagnostic techniques and specialized cancer care, making more precise diagnoses and individualized plans for managing anemia possible. The increasing focus on enhancing the well-being of cancer patients has prompted hospitals to place a premium on excellent chemotherapy-induced anemia management, which has contributed to their fast expansion in this sector.
The North American chemotherapy-induced anemia market is expected to register the highest market share in revenue in the near future. It can be attributed to the focus on establishing targeted treatments, elevated cancer rates, and a dramatic rise in public understanding of cancer prevention and treatment options. The rising need for therapies for chemotherapy-induced anemia is also fueling the expansion of this industry. In addition, Asia Pacific is anticipated to grow rapidly in the global chemotherapy-induced anemia market due to the region's vast population and the growing need for top-notch healthcare, the growing number of older adults, and the subsequent demand for better healthcare services and the need for cutting-edge medical technology.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 2.4 Bn |
|
Revenue Forecast In 2031 |
USD 3.9 Bn |
|
Growth Rate CAGR |
CAGR of 6.5% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Anemia, By Treatment Type, By Drug Type, By End-user and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Astellas Pharma Inc., Blausen Medical, Dr. Reddy’s Laboratories Ltd., Elsevier Inc., F. Hoffmann-La Roche Ltd, FibroGen, Inc., GlaxoSmithKline PLC, Healio, Johnson & Johnson, Karger AG, Novartis AG, and Pfizer Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Chemotherapy Induced Anemia Market Snapshot
Chapter 4. Global Chemotherapy Induced Anemia Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Range of Anemia Estimates & Trend Analysis
5.1. by Range of Anemia & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Range of Anemia:
5.2.1. Mild Anemia
5.2.2. Moderate Anemia
5.2.3. Severe Anemia
5.2.4. Life-Threatening Anemia
Chapter 6. Market Segmentation 2: by Treatment Type Estimates & Trend Analysis
6.1. by Treatment Type & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Treatment Type:
6.2.1. RBC Transfusion
6.2.2. Erythropoiesis-stimulating agents (ESAs)
6.2.3. Iron Supplementation
Chapter 7. Market Segmentation 3: by Drug Type Estimates & Trend Analysis
7.1. by Drug Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Drug Type:
7.2.1. Epogen Injection
7.2.2. Procrit Injection
7.2.3. Androxy Oral
7.2.4. Aranesp Injection
7.2.5. Epoetin Alfa Injection
7.2.6. Others
Chapter 8. Market Segmentation 4: by End-User Estimates & Trend Analysis
8.1. by End-User & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End-User:
8.2.1. Hospitals
8.2.2. Specialty Clinics
8.2.3. Ambulatory Surgical Centers
8.2.4. others
Chapter 9. Chemotherapy Induced Anemia Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.1.2. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.1.3. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.1.4. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.1.5. North America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.2.2. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.2.3. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.2.4. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.2.5. Europe Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.3.2. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.3.3. Asia-Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.3.4. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.3.5. Asia Pacific Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.4.2. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.4.3. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.4.4. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.4.5. Latin America Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Range of Anemia, 2019-2031
9.5.2. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Treatment Type, 2019-2031
9.5.3. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2019-2031
9.5.4. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2019-2031
9.5.5. Middle East & Africa Chemotherapy Induced Anemia Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Astellas Pharma Inc.
10.2.2. Blausen Medical
10.2.3. Dr. Reddy's Laboratories Ltd.
10.2.4. Elsevier Inc.
10.2.5. F. Hoffmann-La Roche Ltd
10.2.6. FibroGen, Inc.
10.2.7. GlaxoSmithKline PLC
10.2.8. Healio
10.2.9. Johnson & Johnson
10.2.10. Karger AG
10.2.11. Novartis AG
10.2.12. Pfizer Inc.
10.2.13. Other Prominent Players
Chemotherapy-Induced Anemia Market-By Type of Anemia
Chemotherapy-Induced Anemia Market-By Treatment Type
Chemotherapy-Induced Anemia Market-By Drug Type
Chemotherapy-Induced Anemia Market-By End-User
Chemotherapy-Induced Anemia Market-By Region
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
